FDA 483 - Janssen Biologics B.V. - September 21, 2012
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Janssen Biologics B.V. in Leiden, The Netherlands, was cited for significant issues during an FDA inspection related to its biological bulk drug substance manufacturing. The inspection revealed failures in preventing microbial and endotoxin contamination during production, with numerous out-of-specification events reported. Additionally, the Quality Unit failed to conduct complete investigations and implement timely corrective and preventive actions for these contamination issues.
ID · aaf8436c-365f-4ed0-8b0c-111c7a62a295